Side-by-side · Research reference

RetatrutidevsVesugen

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 2HUMAN-REVIEWED10/41 cited

BAnimal-MechanisticHUMAN-REVIEWED5/43 cited

Retatrutide

Triple-receptor agonist · Phase 3

1–12 mgWeekly doseJastreboff 2023

24.2%Body-weight ↓Jastreboff 2023

~6 daysHalf-life (est)

SQ · Abdomen · Once weekly

Vesugen

Bioregulatory Tripeptide · Vascular Endothelium

3 AATripeptide

Endothelin-1 ↓Atherosclerotic tissue

Ki-67 ↑Aged endothelium

SQ / IM · Protocol varies

01Mechanism of Action

Parameter

Retatrutide

Vesugen

Primary target

GLP-1R + GIPR + Glucagon receptor (triple agonism)Jastreboff 2023

Vascular endothelial cell nucleus — MKI67 gene promoter

Pathway

Triple-receptor activation → ↑insulin (GLP-1+GIP), ↓gastric emptying, ↑lipid handling, ↑energy expenditure (glucagon component)Jastreboff 2023

KED → MKI67 promoter interaction (CATC binding motif -14 to +12 bp) → Ki-67 proliferation protein ↑

Downstream effect

Maximal weight loss across class. Glucagon component drives lipolysis and energy expenditure beyond GLP-1+GIP aloneJastreboff 2023

Normalised endothelin-1 expression in atherosclerotic/restenotic endothelium, restored connexin expression for cell-cell communication, enhanced proliferative capacity in senescent endothelial culturesKozlov 2016 Khavinson 2014

Feedback intact?

—

Not applicable — does not operate via hormone axis

Origin

Synthetic peptide engineered for balanced affinity at three incretin / glucagon receptorsJastreboff 2023

Khavinson bioregulatory peptide school — designed as tissue-specific (vascular) cytomodulator

Antibody development

—

02Dosage Protocols

Parameter

Retatrutide

Vesugen

Standard dose

12 mg / week (max efficacy)Jastreboff 2023

Phase 2 trial dose. Phase 3 dosing TBD.

—

Frequency

Once weekly

Not specified in available literature

Titration schedule

2 mg → 4 mg → 8 mg → 12 mg over 16 weeks

—

Evidence basis

Phase 2 trial; Phase 3 ongoingJastreboff 2023

Animal models (atherosclerosis, restenosis, aging) · Russian case series

Duration

Indefinite for chronic indication (presumed)

Case series report treatment courses in elderly arterial insufficiency

Reconstitution

Investigational; not commercially available

—

Timing

Any time of day

—

Half-life

~6 days (estimated from class)

Not reported

Tripeptides typically cleared rapidly.

Standard dose (reported)

—

Not standardised — Russian clinical case series

Protocols vary; no FDA-approved regimen.

Route

—

Subcutaneous or intramuscular

04Side Effects & Safety

Parameter

Retatrutide

Vesugen

GI symptoms

Nausea, vomiting, diarrhea (very common, dose-dependent)Jastreboff 2023

—

Heart rate

↑ resting HR (3–7 bpm at 12 mg)Jastreboff 2023

—

Glucose handling

Glycemic improvement; rare hyperglycemia from glucagon component

—

Pancreatitis risk

Class warning

—

Thyroid C-cell tumours

Class warning (presumed)

—

Pregnancy / OB

Avoid (insufficient data)

—

Reported adverse events

—

None documented in available abstracts

Injection site

—

Assumed minimal — typical for small peptides

Long-term safety

—

Unknown — no long-term RCT data

Epigenetic mechanism risk

—

Theoretical concern: direct gene promoter interaction — proliferative effects in non-target tissues not characterised

Absolute Contraindications

Retatrutide

·MTC personal or family history (presumed class effect)
·Pregnancy / breastfeeding

Vesugen

—

Relative Contraindications

Retatrutide

·Severe gastroparesis
·History of pancreatitis
·Severe cardiovascular disease (HR signal)

Vesugen

·Active malignancy — proliferative mechanism (Ki-67 upregulation) untested in oncologic context

05Administration Protocol

Parameter

Retatrutide

Vesugen

1. Reconstitution

Investigational peptide. Research vials reconstituted with bacteriostatic water per label.

Lyophilised powder reconstituted with sterile water or bacteriostatic water per supplier protocol. No standardised formulation.

2. Injection site

SQ — abdomen, thigh, or upper arm. Rotate weekly.

Subcutaneous (abdomen, thigh) or intramuscular. Rotate sites if multi-dose protocol.

3. Timing

Once weekly, same day.

No reported circadian or fasting requirement. Russian protocols typically integrated into geroprotective regimens.

4. Storage

Refrigerate 2–8 °C. Light-protected.

Lyophilised: refrigerate 2–8 °C, light-protected. Reconstituted: use immediately or refrigerate per supplier guidance (typically <7 days).

5. Needle

27–31G, 4–8 mm insulin syringe.

—

06Stack Synergy

Retatrutide

— no documented stacks

Vesugen

+ Thymalin

Multi-pathway

View Thymalin →

Both from Khavinson bioregulatory school. Thymalin targets thymic/immune axis, Vesugen targets vascular endothelium. Rationale: multi-system geroprotection in elderly — immune senescence + vascular aging. Documented in Khavinson-tradition protocols combining tissue-specific peptides for poly-organ rejuvenation. No direct synergy study; combinatorial logic based on distinct target tissues.

Vesugen: Per protocol (SQ/IM)
Thymalin: Per protocol (SQ/IM)
Frequency: Sequential or concurrent per geroprotective protocol
Primary benefit: Multi-system age-related decline mitigation (vascular + immune)